GABRA-1: A GABA(A) Receptor Subunit (G2569)

Target Name: GABRR1

NCBI ID: G2569

GABRR1

Other Name(s): GABA(A) receptor subunit rho-1 | gamma-aminobutyric acid type A receptor subunit rho1 | Gamma-aminobutyric acid (GABA) A receptor, rho-1 | Gamma-aminobutyric acid receptor subunit rho-1 | gamma-aminobutyric acid (GABA) receptor, rho 1 | gamma-aminobutyric acid type A receptor rho1 subunit | Gamma-aminobutyric acid type A receptor subunit rho1, transcript variant 4 | GBRR1_HUMAN | Gamma-aminobutyric acid (GABA) receptor, rho 1 | GABA(A) receptor, rho 1 | Gamma-aminobutyric acid receptor subunit rho-1 (isoform a) | gamma-aminobutyric acid (GABA) A receptor, rho-1 | MGC163216 | OTTHUMP00000209035 | BA135P14.1 (gamma-aminobutyric acid (GABA) receptor, rho 1) | bA135P14.1 (gamma-aminobutyric acid (GABA) receptor, rho 1) | GABRR1 variant 1 | GABA(C) receptor | Gamma-aminobutyric acid receptor subunit rho-1 (isoform c) | Gamma-aminobutyric acid type A receptor subunit rho1, transcript variant 1 | GABRR1 variant 4

GABRA-1: A GABA(A) Receptor Subunit

GABRR1 (GABA(A) receptor subunit rho-1) is a protein that is expressed in many different tissues and cells in the body. It is a subunit of the GABA(A) receptor, which is a well-known neurotransmitter receptor that plays a crucial role in the regulation of neural activity.

The GABRA

Protein Name: Gamma-aminobutyric Acid Type A Receptor Subunit Rho1

Functions: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission

The "GABRR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABRR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets